RUA Life shares rise as newly bought ABISS turns profit in 2024

(Alliance News) - RUA Life Sciences PLC on Monday celebrates its newly acquired manufacturer of a ...

Alliance News 3 February, 2025 | 2:26PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - RUA Life Sciences PLC on Monday celebrates its newly acquired manufacturer of a number of long-term implantable devices swinging to a profit in 2024.

RUA Life Sciences is the holding company of multiple medical device businesses.

RUA said its newly bought Saint Etienne, France-based company Analytic Biosurgical Solutions, known as ABISS, has turned a profit in 2024.

ABISS's revenue rose about 7% in 2024 to EUR2.3 million. Notably, it turned to a pretax profit of EUR46,000 in 2024, from a loss of EUR352,000 in 2023.

RUA said ABISS has overcome supply chain challenges it faced in the first nine months of 2024.

RUA Chief Executive Officer Bill Brown said: "Abiss is demonstrating itself to be a very high-quality business, and the combination with RUA allows a number of strategic opportunities to be pursued in further developing the group."

Back in September, RUA bought ABISS for EUR80,000 from the French liquidator of IPSA SAS, its former parent company.

Further, last week Wednesday RUA announced a new multi-year supply contract with a global customer with an initial annual value of over GBP500,000. The contract is within RUA's medical device & components business unit.

"The revenue expected during the current calendar year is anticipated to grow over time with a potential value over a five-year period of GBP3.3 million. This new contract represents a six-fold increase on the level of business undertaken for the customer prior to commencing work on the project," RUA said.

RUA Life shares rose 8.0% to 13.50 pence each on Monday afternoon in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
RUA Life Sciences PLC 13.70 GBX 7.45 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures